Drugs / JVS-100
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01657045 | Jul 2012 → Dec 2013 | — | SironRX Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01961726 | Oct 2013 → Aug 2015 | heart failure | Juventas Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01643590 | Jul 2012 → Oct 2014 | heart failure | Juventas Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT01410331 | Mar 2012 → Jul 2014 | limb ischemia | Juventas Therapeutics, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02544204 Comparator | Nov 2015 → Sep 2017 | peripheral arterial disease | Juventas Therapeutics, Inc. | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-11-22 | Astellas Pharma Inc | Astellas Executes License Agreement with an Option to Acquire JVS-100 Gene Therapy Program from Juventas astellas.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JVS-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01961726 ↗ |
| Action | Activate | “activates endogenous regenerative repair pathways” PMID 30786835 ↗ Feb 2019 |
| Modality | Other / unclassified | “a non-viral gene therapy” PMID 30786835 ↗ Feb 2019 |
| Route | Intramuscular | “JVS-100 will be delivered by direct intramuscular injection into the limbs of study subjects.” NCT01410331 ↗ |